Inovum (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil selectively blocks the AT1 receptors for angiotensin II, preventing the peptide from causing vasoconstriction, aldosterone release, and sympathetic activation. By inhibiting this pathway, it promotes vasodilation and reduces fluid retention, which together lower systemic vascular resistance and arterial pressure.

The specific dose of Inovum is determined by the prescribing clinician based on the patient’s blood‑pressure readings, previous therapy, and overall health status. The prescriber selects the appropriate strength and titrates as needed to achieve target blood‑pressure goals while monitoring for efficacy and safety.

Inovum is classified as pregnancy category D, indicating evidence of risk to the fetus and that it should be avoided unless the potential benefit justifies the risk. It is also not recommended during breastfeeding because the active ingredients can pass into breast milk and may affect the infant. Alternative therapies are preferred for pregnant or nursing women.

To place an order, visit the product page for Inovum on the GNH India website (gnhindia.com), enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inovum offers the convenience of a single tablet that combines an ARB with a calcium‑channel blocker, which can improve adherence compared with taking two separate medications. Compared with monotherapy, the combination provides greater blood‑pressure reduction and may be more effective in patients whose pressure is not controlled on a single agent. It shares a similar safety profile to its individual components, but the fixed‑dose may limit dose flexibility.

Inovum tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources, and discard any tablets that appear discoloured or damaged.

Inovum is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed, crushed, or split unless the prescriber specifically advises otherwise. Consistent daily dosing helps maintain stable blood‑pressure control.

The most serious adverse reactions to Inovum include severe hypotension, angioedema, and significant renal impairment, especially when used with other drugs that affect the renin‑angiotensin system or potassium balance. Patients should be monitored for sudden drops in blood pressure, swelling of the face or throat, and changes in kidney function, and seek immediate medical attention if these occur.

Inovum is contraindicated in individuals with known hypersensitivity to olmesartan, amlodipine, or any excipients in the formulation. It should also be avoided in patients with severe hepatic impairment, those who are pregnant, and anyone currently receiving an ACE inhibitor or another ARB. Patients with a history of angioedema or significant renal dysfunction should discuss alternative treatments with their physician.